RA PHARMACEUTICALS,INC. (NASDAQ:RARX) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k
-
0

RA PHARMACEUTICALS,INC. (NASDAQ:RARX) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders.

On June28, 2018, Ra Pharmaceuticals,Inc. (the “Company”) held its Annual Meeting of Stockholders. A total of 26,263,521 shares of common stock were present in person or represented by proxy at the meeting, representing approximately 81.3 percent of the Company’s outstanding common stock as of the April30, 2018 record date. The following are the voting results for the proposals considered and voted upon at the meeting, all of which were described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April27, 2018 and amended and restated on May7, 2018.

Item 1 — Election of two ClassII directors to serve until the 2021 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified.

NOMINEE

VotesFOR

VotesWITHHELD

BrokerNon-Votes

Robert Heft, Ph.D.

21,291,120

2,596,122

2,376,279

Rajeev Shah

20,915,603

2,971,639

2,376,279

Item 2 — Ratification of the appointment of Deloitte& Touche LLP as the Company’s independent registered public accounting firm for the year ending December31, 2018.

VotesFOR

VotesAGAINST

VotesABSTAINED

BrokerNon-Votes

26,216,872

45,553

1,096

Based on the foregoing votes, Robert Heft, Ph.D. and Rajeev Shah were elected as ClassII directors and Item 2 was approved.


About RA PHARMACEUTICALS,INC. (NASDAQ:RARX)

Ra Pharmaceuticals, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade. It has leveraged the Extreme Diversity peptide chemistry platform to develop a portfolio of products that selectively inhibit the complement system and other immune targets. Its main program, RA101495, is a macrocyclic peptide inhibitor of complement component 5 (C5), which is in Phase I stage of development for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). RA101495 binds a site on the C5 protein to inhibit cleavage into C5a and C5b, thereby preventing red blood cell lysis by inhibiting the production and assembly of the membrane attack complex (MAC). RA101495 is being developed as an alternative to eculizumab therapy for patients with PNH.